CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
1.5747
0.64%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.1506
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024346 %
Charges from full value of position ($-4.63)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002124 %
Charges from full value of position ($0.40)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.5647
Open 1.5547
1-Year Change 55.86%
Day's Range 1.5147 - 1.5747
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 1.5647 -0.0900 -5.44% 1.6547 1.6547 1.5147
Dec 16, 2024 1.5147 -0.0400 -2.57% 1.5547 1.5947 1.5147
Dec 13, 2024 1.6147 -0.0700 -4.16% 1.6847 1.7547 1.5347
Dec 12, 2024 1.6647 0.0200 1.22% 1.6447 1.7547 1.6347
Dec 11, 2024 1.5147 -0.1600 -9.55% 1.6747 1.6847 1.5147
Dec 10, 2024 1.6747 -0.0600 -3.46% 1.7347 1.7347 1.6547
Dec 9, 2024 1.6147 0.0000 0.00% 1.6147 1.7247 1.5547
Dec 6, 2024 1.6547 0.0000 0.00% 1.6547 1.7247 1.6447
Dec 5, 2024 1.6347 0.0000 0.00% 1.6347 1.6947 1.6347
Dec 4, 2024 1.5647 -0.1400 -8.21% 1.7047 1.7047 1.5647
Dec 3, 2024 1.6847 0.1000 6.31% 1.5847 1.7247 1.5147
Dec 2, 2024 1.6247 -0.1700 -9.47% 1.7947 1.7947 1.6247
Nov 29, 2024 1.7847 -0.0500 -2.73% 1.8347 1.8547 1.7847
Nov 27, 2024 1.8847 0.0100 0.53% 1.8747 1.9347 1.7647
Nov 26, 2024 1.7847 0.0900 5.31% 1.6947 1.8447 1.6947
Nov 25, 2024 1.6347 0.0100 0.62% 1.6247 1.7547 1.6247
Nov 22, 2024 1.6447 0.0600 3.79% 1.5847 1.7047 1.5847
Nov 21, 2024 1.6847 0.0800 4.99% 1.6047 1.6847 1.5747
Nov 20, 2024 1.6347 -0.0400 -2.39% 1.6747 1.6747 1.5947
Nov 19, 2024 1.6247 -0.0400 -2.40% 1.6647 1.6947 1.5547

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

BeyondSpring Inc. Company profile

About Beyondspring Inc

BeyondSpring Inc. is a global biopharmaceutical company that is focused on developing immuno-oncology cancer therapies. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).

Financial summary

BRIEF: For the nine months ended 30 September 2021,Beyondspring Inc revenues increased from $0K to $1M. Netloss increased 26% to $54.7M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsGeneral and administrative - Balancing increase from $10.2Mto $22M (expense), Stock-based Compensation in SGA increaseof 76% to $3.7M (expense).

Industry: Bio Therapeutic Drugs

28 Liberty Street
39th Floor
NEW YORK
NEW YORK 10005
US

People also watch

US100

22,000.70 Price
+0.160% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

104,103.90 Price
-1.970% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

XRP/USD

2.48 Price
-5.310% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01235

ETH/USD

3,860.12 Price
-1.840% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading